We've created a unique single-molecule platform to answer your most challenging questions
ScopeSys is a Canadian company with a mission to help translate the value of our unique single-molecule imaging platform to real-world applications, such as the advancement of new medicines, and offers career opportunities to young Canadian biophysicists and bioengineers. Spun out of the LeslieLab at UBC, this company is translating the value of its unique multi-scale microscopy technology platform via select industry partnerships. Through synergistic and strategic partnerships, we aim to maximize the potential for social benefit of our unique technology and capabilities. Potential impacts may eventually include widespread use of our technology to help enable and accelerate the design, development and discovery of drugs and vaccines. Other partners in this effort include Fasken, UBC, McGill, and Harvard, as well as our Vancouver-based commercial advisory board. ScopeSys has also placed early-access technology packages in the labs of select researchers to pursue a range of applications.
Sabrina Leslie, Ph.D.
Chief Scientific Officer, President and Founder
Sabrina is co-founder of ScopeSys and lead inventor of the CLiC technology. She leads a single-molecule microscopy group in the Michael Smith Labs as well as the Physics and Astronomy Department at the University of British Columbia. She has pioneered the research and development of the CLiC technology, while investigating DNA, protein, RNA, and nanoparticle applications. She earned her B.Sc. in Honours Math and Physics at UBC in 2002 and Ph.D. in Physics at U.C. Berkeley in 2008. From 2009 to 2011, she was a Mary Fieser post-doctoral fellow in the Department of Chemistry and Chemical Biology at Harvard, where she co-invented and began to develop the CLiC technology with Adam Cohen. Sabrina was a professor in the Physics Department at McGill University from 2012 to 2020 and relocated with her team to UBC in 2021.
Romain Berti, Ph.D.
Chief Technology Officer
Romain leads the software development team, integrating image acquisition and data analysis into a robust software platform, and other aspects of day-to-day operations of the company. His work is focused on designing and developing the analysis algorithms and user interface for the ScopeSys microscopy platform as well as company operations. Romain obtained his MSc in Molecular and Cellular Biology and his PhD in Biophysics from the Pierre and Marie Curie University in Paris, followed by management training at HEC Montreal.
Andree Wild, P.Eng.
Andree leads hardware development and other engineering projects at ScopeSys. She was a co-founder of Precision NanoSystems, a Vancouver biotech company which was acquired by Danaher in 2021. During her tenure at PNI she led teams in both R&D and product commercialization as well as working as an individual contributor. She has significant experience in microfluidics, micro and nanoscale manufacturing, scientific instrumentation and user centered design. Andree holds a B.A.Sc in engineering physics from University of British Columbia. She is a co-inventor on nine patent families and holds numerous design patents.
Albert Kamanzi, Ph.D.
Albert is leading the lipid nanoparticle (drug delivery) analytics development team at ScopeSys using the CLiC imaging platform. He earned his B.Sc. and M.Sc. degrees in Physics and Applied physics from the University of Massachusetts Boston, as well as a few years' industry experience, and subsequently earned his PhD in Biophysics at McGill University with Dr. Leslie in 2021. First as a ScopeSys Mitacs Post Doc and subsequently as VP Analytics at ScopeSys, Albert is expert in the biophysics of siRNA- and mRNA-LNPs as seen at high resolution, as well as CLiC microscopy, and has pioneered experiments in this area since 2018 with Dr. Leslie and collaborators.
Ariadne Tuckmantel Bido, Ph.D.
Ariadne is a pivotal scientist at ScopeSys, working on the lipid nanoparticle imaging team to advance drug delivery systems using the CLiC platform. She holds B.Sc. and Ph.D. degrees in Chemistry from the University of Campinas (UNICAMP) in 2013 and the University of Victoria in 2023. Joining ScopeSys in June 2023 as an NMIN post-doc and as a MITACS Postdoctoral fellow in November 2023, Ariadne specializes in understanding the biophysics of mRNA-LNPs at high resolution, as well as CLiC microscopy. She has been forging new branches of experiments in this area since early 2024 with Dr. Leslie, ScopeSys, and collaborators.
Benjamin is a key member of the software development team. His work focuses on developing the CLiC analysis software which includes image processing techniques and machine learning. He earned his B.Sc. in Math & Physics and M.Sc. degrees in mathematics from the University of British Columbia and worked in the software industry for a number of years before joining the ScopeSys team.
Michael is a software engineer on the ScopeSys team. His work focuses on developing software for performing and analyzing new experiments as well as building databases and Python tools. He recently graduated from the Honours Math & Physics program at McGill University.
James Taylor, Ph.D.
Pharmaceutical Applications Advisor
James is a co-founder was the CEO of Precision Nanosystems Inc. (PNI), a company which commercializes scientific instruments and services for developing lipid nanoparticles for drug delivery applications. PNI was acquired by Danaher in 2021 and rebranded as Cytiva in 2023. James has a B.A.Sc. in engineering physics from UBC and a Ph.D. in genetics from the Institute for Systems Biology. Dr. Taylor has worked at the venture capital firm, Accelerator Corporation, and has over a decade of experience in microfluidics, nanotechnology and systems biology. Dr. Taylor is also a member of the Board of Directors of Life Science British Columbia.
Andy is a serial entrepreneur having founded 8 advanced technology startups. Andy was a founder of the entrepreneurship program at the University of British Columbia (e@UBC), where he helped launch over 36 technology and life sciences companies in just 3 years. Andy is a frequent speaker at leading tech and life-science accelerators on topics including entrepreneurship and strategic planning for early-stage companies. He has served on numerous tech industry boards and has been involved in over 20 exits.
Andre Marziali, Ph.D.
Andre is co-founder was the President of Boreal Genomics since 2007, a company which specializes in liquid biopsy for early cancer detection, and was acquired in 2021. Dr. Marziali received his B.A.Sc. in Engineering Physics from UBC in 1989, and his PhD in Physics from Stanford University in 1994. He then worked with Dr. Ron Davis in the Stanford DNA Sequencing Technology Center developing DNA sequencing technologies, and joined UBC as faculty in 1998 where he is now a Professor of Physics and Director of the Engineering Physics Program.
Tim is a co-founder of Aqua M&A, a boutique advisory firm specializing in tech and life-science companies with disruptive intellectual property. Tim has built over a dozen new businesses within startups, mid-size, and large technology firms, and has held a variety of executive positions, most recently as VP Strategic Development at MacDonald Dettwiler and Associates (MDA), one of Canada’s largest technology firms. Tim speaks fluent Japanese and spent over 20 years doing business throughout the Asia Pacific region.